Sara Richeson
Acute Care · Newburgh, INNPI 1720566797
Payments from drug & device makers
What this record shows
Almost everything reported here is food and beverage — 100.0% of the total across 316 separate payments, which is the pattern of a clinician who attends manufacturer presentations rather than one with a consulting arrangement. It is spread thinly across 28 manufacturers, the largest accounting for just 22.3% — the pattern of someone who eats at a lot of different presentations. Among acute care clinicians in IN with any reported payments, this total sits in the top 5% — high for the specialty, which is a reason to read the composition above rather than the number alone.
Across 316 payments — averaging $18.16 each. Meals, travel, consulting and speaking fees, gifts and royalties reported by drug and device makers.
- AbbVie$1K
- Salix Pharmaceuticals, A Division Of Bausch Health US, LLC$1K
- Takeda Pharmaceuticals U.S.A., Inc.$493
- Johnson & Johnson$366
- Gilead$289
- Regeneron Healthcare Solutions, Inc.$269
- plus $2K from 22 others
What the payments were for
- Food & beverage$5,737100%
Most of this is food and beverage — typically meals provided during product presentations at a clinic or hospital. Nationally that is the single largest category of reported payments by count.
General payments by program year
Who reported the general payments
Companies are grouped under their corporate parent — a single manufacturer often files under several CMS reporting entities. Research and ownership payments are counted separately and are not in this table.
| Company | Payments | Total |
|---|---|---|
| AbbVie | 97 | $1,277 |
| Salix Pharmaceuticals, A Division Of Bausch Health US, LLC | 54 | $1,063 |
| Takeda Pharmaceuticals U.S.A., Inc. | 24 | $493 |
| Johnson & Johnson | 17 | $366 |
| Gilead | 17 | $289 |
| Regeneron Healthcare Solutions, Inc. | 11 | $269 |
| Intercept Pharmaceuticals, Inc. | 15 | $254 |
| Madrigal Pharmaceuticals | 5 | $186 |
| Sanofi | 7 | $146 |
| Pfizer | 7 | $141 |
| Ironwood Pharmaceuticals, Inc | 5 | $137 |
| Ardelyx, Inc. | 6 | $123 |
| Braintree Laboratories, Inc. | 6 | $118 |
| Phathom Pharmaceuticals, Inc. | 6 | $113 |
| Lilly USA, LLC | 5 | $102 |
| Amgen | 5 | $96 |
| Boston Scientific | 4 | $88 |
| Organon | 4 | $75 |
| Ferring Pharmaceuticals Inc. | 4 | $72 |
| Merck | 4 | $71 |
| QOL Medical, LLC | 3 | $55 |
| Daiichi Sankyo Inc. | 2 | $50 |
| Bristol Myers Squibb | 3 | $46 |
| Aimmune Therapeutics, Inc. | 1 | $31 |
| Nestle Healthcare Nutrition Inc. | 1 | $27 |
| Alnylam Pharmaceuticals Inc. | 1 | $18 |
| Mauna Kea Technologies, Inc. | 1 | $17 |
| AMAG Pharmaceuticals, Inc. | 1 | $13 |
How this compares
$5,737 in reported general payments places this provider in the 95th percentile of 240 acute care providers in Indiana.
Medicare billing
What this is not: this is the amount Original Medicare Part B allowed for services this provider billed in 2024. It is not their income. It excludes Medicare Advantage — now more than half of all Medicare enrollment — along with Medicaid and all commercial insurance, and it is gross practice revenue before staff, rent, supplies and malpractice premiums. CMS also suppresses any figure covering ten or fewer patients, so low-volume providers appear smaller than they are.
Most prescribed under Part D
| Drug | Claims | Cost to plans & patients |
|---|---|---|
| StelaraUstekinumab | 26 | $724,967 |
| XifaxanRifaximin | 28 | $84,076 |
| LinzessLinaclotide | 61 | $48,945 |
| RezdiffraResmetirom | 12 | $46,795 |
| MotegrityPrucalopride Succinate | 17 | $16,677 |
| MovantikNaloxegol Oxalate | 34 | $13,226 |
| Lubiprostone | 64 | $6,853 |
| Dexlansoprazole DrDexlansoprazole | 18 | $6,059 |
| Budesonide DrBudesonide | 17 | $2,543 |
| Pantoprazole Sodium | 241 | $2,530 |
| Dicyclomine Hcl | 75 | $2,356 |
| Esomeprazole Magnesium | 27 | $2,236 |
| Omeprazole | 177 | $1,762 |
| Colestipol Hcl | 30 | $1,289 |
| Ondansetron OdtOndansetron | 39 | $732 |
Paid to pharmacies, not to this prescriber.
Companies that both paid and supply prescribed drugs
These companies both reported payments to this provider and make drugs the provider prescribed under Medicare Part D in 2024. For most specialties this overlap is expected — a cardiologist who is paid by a cardiology drugmaker also treats heart disease. It is shown so the reader can see it, not because it implies anything on its own.
| Company | Paid to this provider | Part D cost of their drugs |
|---|---|---|
| Johnson & JohnsonStelara | $366 | $724,96726 claims |
| Salix Pharmaceuticals, A Division Of Bausch Health US, LLCXifaxan | $1,063 | $84,07628 claims |
| AbbVieLinzess | $1,277 | $48,94561 claims |
| Madrigal PharmaceuticalsRezdiffra | $186 | $46,79512 claims |
| Takeda Pharmaceuticals U.S.A., Inc.Motegrity | $493 | $16,67717 claims |
Reading this fairly. The Part D column is what drug plans and patients paid pharmacies — this provider received none of it, and it reflects how many patients they treat and what those drugs cost. Against peers, this provider's reported payments sit in the 95th percentile of 240 acute care providers in Indiana.
Other acute care in Newburgh
- Wen CaiNewburgh$12K
- Sarah LongNewburgh$8K
- Aaron HoldermanNewburgh$8K
- Abby DossettNewburgh$5K
- Rachael DrakeNewburgh$5K
- Ladonna SchmidtNewburgh$5K
- Katie LuigsNewburgh$5K
- Carolyn McDonaldNewburgh$4K
- Melissa LorenzJeffersonville$19K
- Amara Wright-TerryMunster$17K
Where these figures come from
- Payments: CMS Open Payments, program years 2019–2025 (publication P06302026_06032026).
- Billing: Medicare Physician & Other Practitioners, data year 2024. Original Medicare Part B only.
- Identity: NPPES NPI Registry, July 2026.